Pharmaceuticals, Biotechnology & Life Sciences

Gilead Sciences shares insider sales, yet its cutting‑edge antiviral pipeline—GS‑NAT‑001, GS‑MEC‑101, GS‑BRAV‑01—shows promise for COVID‑19 and emerging pathogens.

Discover how Sandoz’s new generic semaglutide and emicizumab biosimilar partnership boost affordable diabetes & hemophilia care.

Genmab’s share steadiness amid market swings highlights the company’s quiet yet strategic oncology focus—watch for upcoming trials, partnerships, and M&A to gauge its future upside.

Swiss healthcare’s future hinges on navigating tighter reimbursement, boosting tech adoption, and cutting operational costs to keep quality and profits high.

Inside Roivant Sciences’ latest SEC Form 4 filings: two directors sold ~9,000 shares under Rule 10(b)(5), revealing routine insider trading without shifting board control or ownership stakes.

Regeneron’s pozelimab‑cemdisiran combo targets C5 production and activity, offering stronger hemolysis control for PNH patients who fall short on current anti‑C5 drugs.

Recordati honors Dr. Laura Broutier with the 12th Arrigo Recordati Prize for her DISARMS research, uncovering low‑toxicity therapies that could transform treatment of rare fusion‑negative rhabdomyosarcoma.

Explore how Sartorius AG’s modest 1.4% rise fuels TecDAX’s steady 10% year‑to‑date growth, highlighting its resilience and role in tech‑biotech portfolio diversification.

Kerendia gets FDA approval for type‑1 diabetes‑related CKD, offering the first new treatment in 30 years and boosting Bayer’s renal portfolio.

Merck KGaA strengthens its lead in healthcare analytical testing services, offering AI‑driven, GMP‑compliant bioanalysis and stability solutions that meet tightening global regulations and accelerate biopharma product launches.